ClearSight Therapeutics Receives U.S. Patent Notice of Allowance

DALLAS - EntSun -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases

Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications

DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."

The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.

More on EntSun News

• Montreal Father Builds Mens Clothing Brand in Sizes XS-5XL After Spotting a Gap Nobody Would Fill
• Hispaniola Cigars Distributor Honors the Taino and the Native Nations of the Americas
• Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
• Tickets On Sale Now for Chilling Horror-Thriller, 'One Eye Open'
• Mirada Lagoon to host Game On! Triathlon on Nov. 15

"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."

"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."

In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.

More on EntSun News

• Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
• Colony Ridge Fall Festival: Two Days of Free Family Fun in Cleveland, Texas
• Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
• Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
• Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX

About ClearSight Therapeutics

ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.

Media Contact

ClearSight Therapeutics
info@clearsighttx.com
972-983-7761